<p>/PRNewswire/ -- 一项新的研究表明，使用必需磷脂（Essentiale）治疗可使肝脏脂肪减少 2.5 倍，显著改善疲劳，并改善代谢功能障碍相关脂肪肝病（MASLD，亦称 “脂肪肝”）患者的血糖控制，效果优于单纯的饮食和运动。</p>
<p>这一结果来自于 Essentiale（Opella 品牌）进行的 EXCEL 临床试验——一项多中心、随机、双盲、安慰剂对照的研究，也是首个测试必需磷脂（EPLs）的此类研究。该研究考察了合并有 2 型糖尿病、高脂血症或肥胖等共病的 MASLD 患者。</p>
<p>MASLD 是全球最普遍的慢性肝病，估计影响约 30% 的成年人口，预计到 2040 年，全球超过 55% 的成年人将受到影响 [1]。</p>
<p>脂肪肝常被视为一种 “隐性” 疾病，通常伴随有一系列令人衰弱的症状，如腹痛、疲劳、睡眠问题、腹胀、抑郁症状、焦虑和代谢风险。</p>
<p><strong>诺伯特·斯特凡教授，图宾根大学临床与实验糖尿病学讲座教授。</strong>“这项开创性的研究标志着目前生活在 MASLD 中的数百万人的重要时刻。EXCEL 研究强调了早期干预的临床重要性，并弥合了科学证据与患者体验之间的差距。通过展示肝脏脂肪减少和疲劳改善的可测量进展，这项研究强化了一个重要的信息：有效的、基于证据的选择确实存在，可以改变结果，并为 MASLD 患者恢复充满活力的生活带来希望。”</p>
<p>EXCEL 研究使用现代非侵入性成像技术测量肝脏脂肪，并结合经过验证的特定疾病问卷评估治疗对患者福祉的影响。主要试验结果显示，当与饮食和运动结合使用时，必需磷脂与以下结果相关：</p>
<ul>
<li>与单纯的生活方式干预相比，肝脏脂肪减少 2.5 倍，测量方法为 FibroScan CAP（控制衰减参数）。</li>
<li>患者报告的疲劳显著改善，这是 MASLD 的主要且常被忽视的症状。该结果通过经过验证的 CLDQ-MASLD 评分正式评估，这是一个针对慢性肝病患者的标准化福祉测量工具。</li>
<li>研究还指出，EPLs 治疗显著降低了 HbA1c 水平，这是 2 型糖尿病患者血糖控制的关键指标，使得这一发现对大量合并有代谢疾病的 MASLD 患者尤为相关。</li>
</ul>
<p><strong>尼昆·萨克尔，Essentiale 全球品牌总经理，Opella。</strong>“EXCEL 研究证明了时机的重要性。当 MASLD 在早期被发现时，许多病例是可以逆转的。这种基于证据的治疗，结合必需磷脂、饮食和运动，积极减少肝脏脂肪，并直接应对令人衰弱的疲劳，改变全球数十亿脂肪肝患者的结果。”</p>
<p>完整的研究方法和发现已发表在 <strong>Liver International</strong>：</p>
<p>https://onlinelibrary.wiley.com/doi/10.1111/liv.70601。</p>
<p>[1] Bellentani S., Scaglioni F., Marino M., 和 Bedogni G.，&#34;非酒精性脂肪肝病的流行病学，&#34; Digestive Diseases 28, no. 1 (2010): 155–161。</p>
<p>来源：Opella</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDI3Jk5ld3NJdGVtSWQ9TE40MzE4OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjcwNzEzUFJfTkVXU19VU1BSX19fX19MTjQzMTg5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDI3Jk5ld3NJdGVtSWQ9TE40MzE4OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjcwNzEzUFJfTkVXU19VU1BSX19fX19MTjQzMTg5"/></p>

赛诺菲集团

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

<p>一项新的研究，即 EXCEL 临床试验显示，与单纯依靠饮食和运动相比，使用必需磷脂（Essentiale）治疗代谢功能障碍相关脂肪肝病（MASLD）患者的肝脏脂肪减少了 2.5 倍，并显著改善了疲劳感和血糖控制。这项开创性的研究强调了对数百万受此普遍慢性肝病影响的患者进行早期干预和有效治疗选择的重要性</p>

<p>, /PRNewswire/ -- A new study has established that treatment with essential phospholipids (Essentiale) resulted in a 2.5 times greater reduction in liver fat, significant improvement in fatigue and improvement of glycaemic control in individuals with Metabolic dysfunction–Associated Steatotic Liver Disease (MASLD) - also known as 'Fatty Liver Disease' - than diet and exercise alone.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 一项新的研究表明，使用必需磷脂（Essentiale）治疗可使肝脏脂肪减少 2.5 倍，显著改善疲劳，并改善代谢功能障碍相关脂肪肝病（MASLD，亦称 “脂肪肝”）患者的血糖控制，效果优于单纯的饮食和运动。</p>
</div><p>The results were found by the EXCEL clinical trial from Essentiale (an Opella brand) - a multi-centre, randomized, double-blind, placebo-controlled study and the first of its kind to test essential phospholipids (EPLs). The study examined MASLD patients with comorbidities such as type 2 diabetes, hyperlipidaemia, or obesity.</p>
<div class="lb-trans"><p>这一结果来自于 Essentiale（Opella 品牌）进行的 EXCEL 临床试验——一项多中心、随机、双盲、安慰剂对照的研究，也是首个测试必需磷脂（EPLs）的此类研究。该研究考察了合并有 2 型糖尿病、高脂血症或肥胖等共病的 MASLD 患者。</p>
</div><p>MASLD is the most prevalent chronic liver disease worldwide, affecting an estimated 30% of the adult population, with projections indicating over 55% of adults worldwide will be affected by 2040[1].</p>
<div class="lb-trans"><p>MASLD 是全球最普遍的慢性肝病，估计影响约 30% 的成年人口，预计到 2040 年，全球超过 55% 的成年人将受到影响 [1]。</p>
</div><p>Often considered a &#34;silent&#34; condition, fatty liver disease is frequently associated with a debilitating constellation of symptoms such as abdominal pain, fatigue, sleep issues, bloating, depressive symptoms, anxiety and metabolic risks.</p>
<div class="lb-trans"><p>脂肪肝常被视为一种 “隐性” 疾病，通常伴随有一系列令人衰弱的症状，如腹痛、疲劳、睡眠问题、腹胀、抑郁症状、焦虑和代谢风险。</p>
</div><p><strong>Professor Norbert Stefan, Holder of the Chair of Clinical and Experimental Diabetology at the University of Tübingen.</strong>&#34;This groundbreaking research marks an important moment for the millions of people currently living with MASLD. The EXCEL study underscores the clinical importance of early intervention and bridges the gap between scientific evidence and patient experience. By demonstrating measurable improvements in liver fat reduction and improvement of fatigue, this study reinforces the vital message that effective, evidence-based options exist to transform outcomes and restore hope for a more energized life in people with MASLD.&#34;</p>
<div class="lb-trans"><p><strong>诺伯特·斯特凡教授，图宾根大学临床与实验糖尿病学讲座教授。</strong>“这项开创性的研究标志着目前生活在 MASLD 中的数百万人的重要时刻。EXCEL 研究强调了早期干预的临床重要性，并弥合了科学证据与患者体验之间的差距。通过展示肝脏脂肪减少和疲劳改善的可测量进展，这项研究强化了一个重要的信息：有效的、基于证据的选择确实存在，可以改变结果，并为 MASLD 患者恢复充满活力的生活带来希望。”</p>
</div><p>The EXCEL study used modern, non-invasive imaging to measure liver fat alongside a validated, disease-specific questionnaire to assess the treatment's impact on patient wellbeing. The main trial results showed that, when used in addition to diet and exercise, essential phospholipids were associated with:</p>
<div class="lb-trans"><p>EXCEL 研究使用现代非侵入性成像技术测量肝脏脂肪，并结合经过验证的特定疾病问卷评估治疗对患者福祉的影响。主要试验结果显示，当与饮食和运动结合使用时，必需磷脂与以下结果相关：</p>
</div><ul>
<li>A 2.5 times greater reduction in liver fat compared with lifestyle intervention alone, as measured by FibroScan CAP (Controlled Attenuation Parameter).</li>
<li>A statistically significant improvement in patient-reported fatigue, a primary and often overlooked symptom of MASLD. This outcome was formally assessed using the validated CLDQ-MASLD score, a standardized measure of well-being in individuals with chronic liver disease.</li>
<li>The study also noted that treatment with EPLs significantly reduced HbA1c levels, a key marker for glycemic control in patients with type 2 diabetes, making the findings particularly relevant for the large percentage of MASLD patients with co-existing metabolic conditions.</li>
</ul>
<div class="lb-trans"><ul>
<li>与单纯的生活方式干预相比，肝脏脂肪减少 2.5 倍，测量方法为 FibroScan CAP（控制衰减参数）。</li>
<li>患者报告的疲劳显著改善，这是 MASLD 的主要且常被忽视的症状。该结果通过经过验证的 CLDQ-MASLD 评分正式评估，这是一个针对慢性肝病患者的标准化福祉测量工具。</li>
<li>研究还指出，EPLs 治疗显著降低了 HbA1c 水平，这是 2 型糖尿病患者血糖控制的关键指标，使得这一发现对大量合并有代谢疾病的 MASLD 患者尤为相关。</li>
</ul>
</div><p><strong>Nikunj Thakker Global Brand General Manager Essentiale, Opella.</strong>&#34;The EXCEL study proves that timing is everything. When caught early, a significant portion of MASLD cases can be reversible. This evidence-based treatment, using essential phospholipids combined with diet and exercise, actively reduces liver fat and tackles debilitating fatigue head-on, changing outcomes for the billions globally living with Fatty Liver Disease.&#34;</p>
<div class="lb-trans"><p><strong>尼昆·萨克尔，Essentiale 全球品牌总经理，Opella。</strong>“EXCEL 研究证明了时机的重要性。当 MASLD 在早期被发现时，许多病例是可以逆转的。这种基于证据的治疗，结合必需磷脂、饮食和运动，积极减少肝脏脂肪，并直接应对令人衰弱的疲劳，改变全球数十亿脂肪肝患者的结果。”</p>
</div><p>The full study methodology and findings were published in <strong>Liver Internationa</strong> l:</p>
<div class="lb-trans"><p>完整的研究方法和发现已发表在 <strong>Liver International</strong>：</p>
</div><p>https://onlinelibrary.wiley.com/doi/10.1111/liv.70601.</p>
<div class="lb-trans"><p>https://onlinelibrary.wiley.com/doi/10.1111/liv.70601。</p>
</div><p>[1] Bellentani S., Scaglioni F., Marino M., and Bedogni G., &#34;Epidemiology of Non–Alcoholic Fatty Liver Disease,&#34; Digestive Diseases 28, no. 1 (2010): 155–161.</p>
<div class="lb-trans"><p>[1] Bellentani S., Scaglioni F., Marino M., 和 Bedogni G.，&#34;非酒精性脂肪肝病的流行病学，&#34; Digestive Diseases 28, no. 1 (2010): 155–161。</p>
</div><p>SOURCE Opella</p>
<div class="lb-trans"><p>来源：Opella</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDI3Jk5ld3NJdGVtSWQ9TE40MzE4OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjcwNzEzUFJfTkVXU19VU1BSX19fX19MTjQzMTg5" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LN43189&amp;Transmission_Id=202604270713PR_NEWS_USPR_____LN43189&amp;DateId=20260427"/></p>

07:13 ETThe EXCEL - First-of-its-kind study highlights critical role of essential phospholipids in improving Fatty Liver Disease

prnewswire

美国制药 ETF - iShares

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

赛诺菲

07:13 ETEXCEL - 首次研究强调了必需磷脂在改善脂肪肝疾病中的重要作用